Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
David McGowan MD
To evaluate whether a combination of Zoladex and flutamide used as cytoreductive agents prior to and during definitive radiation therapy improves overall survival over radiation therapy alone in locally confined carcinomas of the prostate
Data for this trial is being collected via the NRG/RTOG Data Center.
Histologically confirmed locally confined adenocarcinoma of the prostate.Clinical stages T1b-2b.No involved nodes.No distant metastases.Karnofsky performance status > = 70.No prior antiandrogen therapy (except as allowed by Section 3.1.5), radiation or chemotherapy
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.